September 25, 2017 |
Newest CRT Pacemaker from Medtronic Approved for US Market
August 26, 2014  | 

Minneapolis, MN - Medtronic, Inc. announced yesterday that the U.S. Food and Drug Administration (FDA) has approved its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P, for indicated patients with heart failure or atrioventricular (AV) block.

The Viva CRT-P includes the Medtronic-exclusive AdaptivCRT® algorithm, which preserves normal heart rhythms and automatically adjusts to the patient's needs, creating a customized therapy for each patient. It is the only algorithm demonstrated to improve heart failure patients' response to the therapy1 and reduce the risk of atrial fibrillation, or AF (as compared to conventional biventricular therapy)2. Recent data also show the AdaptivCRT algorithm reduced 30-day hospital readmissions for heart failure by 47 percent3 and AF-related healthcare utilizations (hospitalizations, emergency department or clinic visits) by 55 percent4 - important benefits since heart failure is a costly problem and represents a leading cause of 30-day hospital readmissions5.

"With the AdaptivCRT algorithm, Viva CRT-P is personalized to the individual patient, adjusting to their needs minute-by-minute," said Daniel Lustgarten, M.D., medical director, Cardiac Electrophysiology Research Laboratory, Fletcher Allen Cardiology, and associate professor, University of Vermont College of Medicine. "With this important new system, patients may respond better to cardiac resynchronization therapy, allowing them to resume daily activities and avoid additional hospitalizations." Continue>

Page | 1 2 3
Suggested Articles